Bird & Bird advises iX Biopharma on rights issue

Bird & Bird is pleased to advise iX Biopharma, a Singapore Exchange (SGX) listed pharmaceutical company, on its renounceable non-underwritten rights issue.

Under the rights issue, each eligible shareholder can subscribe for 11 rights shares at an issue price of S$0.03 per share for every 50 existing shares held in iX Biopharma as at record date 26 June 2024. Additionally, for every two rights shares subscribed, one free warrant will be issued, allowing the holder to purchase one new share in the company at S$0.06.

iX Biopharma is undertaking the rights cum warrants issue to raise funds to, amongst others, advance the development of iXB 401 sublingual semaglutide wafers as a treatment for Type 2 diabetes and obesity, as well as to fund the sales and marketing activities of its innovative supplements including NAD+ sublingual wafers. 

Bird & Bird’s team was led by Corporate Partner Marcus Chow and supported by Counsel Jolie Giouw and Associate Tan Xing Yi.

News & Deals

More News & Deals

News

Bird & Bird continues sponsoring Slush Investor Day, reinforcing commitment to Nordic tech investment

Sep 13 2024

Read More

News

Bird & Bird’s Aviation team in Asia-Pacific ranks 2nd in AFG Legal Survey

Sep 12 2024

Read More

Deal

Bird & Bird has advised East Japan Railway Company in the sale of Decorum Vending Limited

Sep 11 2024

Read More

Deal

Bird & Bird acts as sell-side legal advisor to Vitruvian Partners on its sale of Benify

Sep 06 2024

Read More

Deal

Bird & Bird advise Convion as they join forces with HD Hydrogen

Sep 05 2024

Read More

Deal

Bird & Bird advise Leo Capital on launching their first Nordic Fund

Sep 05 2024

Read More